MedWatch

Global drug groups anticipate growth slowdown in 2019

The world's largest pharma companies anticipate significantly lower sales growth this year compared to 2018. Managers blame the negative development on price pressure, biosimilar competition and saturated markets.

Andreas Daugaard Jørgensen, Managing Director, MSD Denmark. | Foto: MSD Danmark

When Andreas Daugaard Jørgensen, Managing Director of MSD Denmark, evaluates the global medical industry, he sees an industry under pressure.

"In many countries, we experienced an increasing pressure on the health budgets, the competition is getting fiercer in many therapeutic areas, and launching a product has never been more expensive," he says to MedWatch.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier